Each year, SPARK, a Stanford University initiative that provides the education and mentorship in order to advance research discoveries from the bench to the bedside, hosts a diverse group to participate in a 12-day training course in biotech innovation and entrepreneurship. The program provides an understanding of how biotechnology products, such as medical devices, food science, and general medical science, and companies are created, established, managed, advertised, and funded. Ricardo Romero, graduate student of the Integrated Biomedical Sciences program and researcher in the Harper Cancer Research Institute, had the opportunity to attend the program through the Indiana Clinical and Translational Sciences Institute (Indiana CTSI).
For six College of Science students, summer “break” meant advancing their research skills at MD Anderson Cancer Center in Houston, Texas. The students’ experiences were funded by Notre Dame through the generosity of a donor.
Researchers representing four labs across two colleges at Notre Dame have received a four-year, $1.1 million Research Project Grant (R01) from the National Institute of General Medical Sciences at the National Institutes of Health (NIH). The oldest grant mechanism used by the NIH, the R01 provides support for health-related research and development based on the mission of the NIH.
Consider that a human hair is anywhere from 60,000 to 80,000 nanometers in size. A plasmonic nanoparticle, which is a nanoparticle made of noble metals like gold and silver, at their largest are just 100 nanometers, but pack a big punch.
Collaborative research at Notre Dame has demonstrated that electronic interactions play a significant role in the dimensional crossover of semiconductor nanomaterials. The laboratory of Masaru Kuno, professor of chemistry and biochemistry, and the condensed matter theory group of Boldizsár Jankó, professor of physics, have now shown that a critical length scale marks the transition between a zero-dimensional, quantum dot and a one-dimensional nanowire.
This summer the University of Notre Dame welcomed twelve students to campus to participate in the NSF-funded Research Undergraduate Experience (REU) program in analytical chemistry. The 10-week residential program is open to rising sophomore, junior, and senior undergraduates at four-year colleges, with backgrounds in chemistry, biochemistry, biology, chemical engineering, computer science, and mechanical or electrical engineering. It offers students the opportunity to work with Notre Dame faculty on various research projects aimed at solving analytical problems in the developing world, and “teaches students how to engage with a project at the instrumental and experimental design level.”
Brian Baker, recently named the Rev. John A. Zahm Professor of Structural Biology, has been appointed to the position of chair of the Department of Chemistry and Biochemistry, effective July 1, 2016.
Steven Corcelli, associate professor of chemistry and biochemistry, has been selected as a member of the 2016 Fellows of the American Chemical Society. The American Chemical Society (ACS) announced the news today in Chemical & Engineering News.
As Richard Taylor completes a three-year term as associate vice president for research in June of this year, he will continue his research on drug discovery for rare genetic diseases, like NGLY1 deficiency, when he and other members of the Warren Family Research Center for Drug Discovery and Development move into the building this summer.
At the University of Notre Dame, the Molecular Structure Facility (MSF) analyzes organic or inorganic substances at an atomic level, which allows researchers to learn about the three-dimensional structure and connectivity of the compound they have created. Knowing the molecular make-up of substances oftentimes provides faculty, postdoctoral fellows, and graduate students information about whether or not their substance is actually what was intended or even to see if their research is heading in the right direction.
VeriPAD, a startup created by a multidisciplinary team of City College of New York (CUNY) students and recent graduates in collaboration with University of Notre Dame faculty, was awarded the $25,000 Zahn Innovation Center social impact new venture competition grand prize.
Drugs to treat cancer and Alzheimer’s disease usually target the active sites of specific protein molecules sustaining the disease. Traditional drug design views proteins as rigid 3-D objects with active sites consisting of surface-accessible “pockets” with a specific, well-defined structure. Traditional drug design involves finding small molecules with shapes that fit specifically into this pocket. A new study from University of Notre Dame researchers suggests that there are alternative approaches to targeting these proteins, a significant finding for future clinical applications.
Mr. Mike Harper, benefactor of the Harper Cancer Research Institute (HCRI), died this weekend in Omaha NE at the age of 88.
Professors of chemistry and biochemistry, Paul Helquist and Olaf Wiest, together with Frederick Maxfield of Cornell University have received a U.S. patent for potential treatments for Niemann-Pick Type C (NPC) disease. Patent No. 9,333,222, “Histone deacetylase inhibitors as therapeutic agents for Niemann-Pick Type C Disease,” covers the full class of histone deacetylase inhibitors for the genetic, fatal lysosomal storage disorder and related diseases.
Over 70 researchers from a dozen universities in the Midwest gathered at Notre Dame for the 3rd Midwest Ovarian Cancer Coalition workshop to discuss the latest advances in ovarian cancer research.
Seven members of the Pontifical University of Chile (PUC) visited Notre Dame last week to strengthen developing research partnerships and plan upcoming workshops in biochemistry and chemistry, the latest in a partnership between the universities started in 2013.
A novel three-dimensional cell culture technique is making it possible for researchers to study tumors and evaluate potential cancer therapeutics quicker and more efficiently.